Adimab https://validator.w3.org/feed/docs/rss2.html Adimab Provides 2018 Update on Clinical Pipeline News Adimab Provides Update on Pipeline Partnering Homepage Privacy Policy Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies Harnessing the Adimab platform: Case studies exemplifying our path from de novo discovery to clinical advancement Novel anti-CD3 heavy chain-only antibodies for us in T-cell engaging therapeutics Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies Contact Terms of Use Adimab Provides Year-End Update on 2024 Partnership Activities Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38 Adimab Announces Hire of Aaron Sato as Chief Strategy Officer Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows Adimab Announces Substantial Expansion of Research Campus Discovery and engineering of anti-CD3 heavy chain-only antibodies for use in T-cell engaging therapeutics Rapid engineering of soluble T cell receptors for enhanced affinity via a high-throughput yeast-based platform Optimization of analytical tools for nanodisc characterization Engineering a panel of potent and developable anti-CD3 antibodies for conditional activation in the tumor microenvironment Predoctoral Programs Pairing in vivo diversities with a yeast-based platform for integral membrane protein-specific antibody discovery Rapid and efficient generation of panels of T cell engaging (TCE) multispecific antibodies via complementary technologies A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak Biophysical properties of the clinical-stage antibody landscape Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever Broad neutralization of SARS-related viruses by human monoclonal antibodies Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies Adimab Spins Out Adagio Therapeutics to Develop Broadly Protective Coronavirus Antibodies Adimab Publishes Biophysical Performance Metrics that Predict Drug-like Properties of Antibody-based Therapeutics Adimab Provides Year-End Update on 2023 Partnership Activities Adimab Provides Year-End Update on 2022 Partnership Activities Adimab Provides Year-End Update on 2021 Partnership Activities Adimab Provides Year-End Update on 2020 Partnership Activities Adimab Provides Year-End Update on 2019 Partnership Activities Adimab Provides Year-End Update on 2018 Partnership Activities Adimab Provides Year-End Update on 2017 Partnership Activities Adimab Provides Mid-Year Update on 2017 Partnership Activity Adimab Provides 2023 Update on Clinical Pipeline Adimab Provides 2022 Update on Clinical Pipeline A versatile, yeast-based synthetic heavy chain-only antibody platform that facilitates the construction and functional screening of multispecific CD28 T cell engagers Adimab Provides 2021 Update on Clinical Pipeline Adimab Provides 2020 Update on Clinical Pipeline Adimab Provides 2019 Update on Clinical Pipeline ML-based prediction of pairwise antibody epitope binning Who We Are